What can we learn from molecular dynamics simulations for GPCR drug design?

Lundstrom, 2006, Latest development in drug discovery on G protein-coupled receptors, Curr Protein Pept Sci, 7, 465, 10.2174/138920306778559403 Giguere, 2014, Tuning up the right signal: chemical and genetic approaches to study GPCR functions, Curr Opin Cell Biol, 27, 51, 10.1016/j.ceb.2013.11.006 Overington, 2006, How many drug targets are there?, Nat Rev Drug Discov, 5, 993, 10.1038/nrd2199 Wise, 2002, Target validation of G-protein coupled receptors, Drug Discov Today, 7, 235, 10.1016/S1359-6446(01)02131-6 Garland, 2013, Are GPCRs still a source of new targets?, J Biomol Screen, 18, 947, 10.1177/1087057113498418 Fredriksson, 2003, The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints, Mol Pharmacol, 63, 1256, 10.1124/mol.63.6.1256 Lin, 2004, Orphan G protein-coupled receptors: targets for new therapeutic interventions, Ann Med, 36, 204, 10.1080/07853890310024668 Alvarez-Curto, 2011, Novel assay technologies for the discovery of G protein-coupled receptor drugs, Neuromethods, 60, 231, 10.1007/978-1-61779-179-6_12 Beets, 2011, Deorphanizing G protein-coupled receptors by a calcium mobilization assay, Methods Mol Biol, 789, 377, 10.1007/978-1-61779-310-3_25 Boehm, 2013, Chemical probe identification platform for orphan GPCRs using focused compound screening: GPR39 as a case example, ACS Med Chem Lett, 4, 1079, 10.1021/ml400275z Lundstrom, 2009, An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs, Methods Mol Biol, 552, 51, 10.1007/978-1-60327-317-6_4 Stevens, 2013, The GPCR Network: a large-scale collaboration to determine human GPCR structure and function, Nat Rev Drug Discov, 12, 25, 10.1038/nrd3859 Tautermann, 2014, GPCR structures in drug design, emerging opportunities with new structures, Bioorg Med Chem Lett, 24, 4073, 10.1016/j.bmcl.2014.07.009 Congreve, 2011, The use of GPCR structures in drug design, Adv Pharmacol, 62, 1, 10.1016/B978-0-12-385952-5.00011-7 Tautermann, 2011, The use of G-protein coupled receptor models in lead optimization, Futur Med Chem, 3, 709, 10.4155/fmc.11.24 Topiol, 2013, X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?, Expert Opin Drug Discov, 8, 607, 10.1517/17460441.2013.783815 Weyand, 2014, Structure-based drug design applied to GPCRs: the holy grail realized, Biochemist, 36, 23, 10.1042/BIO03602023 Congreve, 2008, Recent developments in fragment-based drug discovery, J Med Chem, 51, 3661, 10.1021/jm8000373 Joseph-McCarthy, 2014, Fragment-based lead discovery and design, J Chem Inf Model, 54, 693, 10.1021/ci400731w Murray, 2012, Experiences in fragment-based drug discovery, Trends Pharmacol Sci, 33, 224, 10.1016/j.tips.2012.02.006 Andrews, 2014, Structure-based and fragment-based GPCR drug discovery, ChemMedChem, 9, 256, 10.1002/cmdc.201300382 Visegrády, 2013, Fragment-based lead discovery on G-protein-coupled receptors, Expert Opin Drug Discov, 8, 811, 10.1517/17460441.2013.794135 Christopher, 2013, Biophysical fragment screening of the beta1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design, J Med Chem, 56, 3446, 10.1021/jm400140q Congreve, 2011, Fragment screening of stabilized G-protein-coupled receptors using biophysical methods, Methods Enzymol, 493, 115, 10.1016/B978-0-12-381274-2.00005-4 Chen, 2012, Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity, ACS Chem Biol, 7, 2064, 10.1021/cb300436c Congreve, 2012, Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design, J Med Chem, 55, 1898, 10.1021/jm201376w Schlyer, 2006, I want a new drug: G-protein-coupled receptors in drug development, Drug Discov Today, 11, 481, 10.1016/j.drudis.2006.04.008 Bertheleme, 2013, Unlocking the secrets of the gatekeeper: methods for stabilizing and crystallizing GPCRs, Biochim Biophys Acta, 1828, 2583, 10.1016/j.bbamem.2013.07.013 Costanzi, 2013, Modeling G protein-coupled receptors and their interactions with ligands, Curr Opin Struct Biol, 23, 185, 10.1016/j.sbi.2013.01.008 Heifetz, 2013, Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis, Biochemistry, 52, 8246, 10.1021/bi401119m Latek, 2013, Towards improved quality of GPCR models by usage of multiple templates and profile-profile comparison, PLoS One, 8, e56742, 10.1371/journal.pone.0056742 Preininger, 2013, Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective, J Mol Biol, 425, 2288, 10.1016/j.jmb.2013.04.011 Rasmussen, 2011, Crystal structure of the beta2 adrenergic receptor-Gs protein complex, Nature, 477, 549, 10.1038/nature10361 Rasmussen, 2011, Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor, Nature, 469, 175, 10.1038/nature09648 Cherezov, 2007, High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor, Science, 318, 1258, 10.1126/science.1150577 Kohlhoff, 2014, Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways, Nat Chem, 6, 15, 10.1038/nchem.1821 Dror, 2011, Activation mechanism of the beta2-adrenergic receptor, Proc Natl Acad Sci, 108, 18684, 10.1073/pnas.1110499108 Bruno, 2012, Molecular dynamics simulations of G protein-coupled receptors, Mol Inform, 31, 222, 10.1002/minf.201100138 Dror, 2012, Biomolecular simulation: a computational microscope for molecular biology, Annu Rev Biophys, 41, 429, 10.1146/annurev-biophys-042910-155245 Zhao, 2014, Molecular dynamics in drug design, Eur J Med Chem Durrant, 2011, Molecular dynamics simulations and drug discovery, BMC Biol, 9, 71, 10.1186/1741-7007-9-71 Harvey, 2012, High-throughput molecular dynamics: the powerful new tool for drug discovery, Drug Discov Today, 17, 1059, 10.1016/j.drudis.2012.03.017 Cozzini, 2008, Target flexibility: an emerging consideration in drug discovery and design, J Med Chem, 51, 6237, 10.1021/jm800562d Feixas, 2014, Exploring the role of receptor flexibility in structure-based drug discovery, Biophys Chem, 186, 31, 10.1016/j.bpc.2013.10.007 Guvench, 2009, Computational fragment-based binding site identification by ligand competitive saturation, PLoS Comput Biol, 5, e1000435, 10.1371/journal.pcbi.1000435 Christ, 2014, Accuracy assessment and automation of free energy calculations for drug design, J Chem Inf Model, 54, 108, 10.1021/ci4004199 Hansen, 2014, Practical aspects of free-energy calculations: a review, J Chem Theory Comput, 10, 2632, 10.1021/ct500161f Tan, 2013, Structure of the CCR5 chemokine receptor–HIV entry inhibitor maraviroc complex, Science, 341, 1387, 10.1126/science.1241475 Chemical Computing Group, 2010 Marti-Renom, 2000, Comparative protein structure modeling of genes and genomes, Annu Rev Biophys Biomol Struct, 29, 291, 10.1146/annurev.biophys.29.1.291 Sali, 1993, Comparative protein modelling by satisfaction of spatial restraints, J Mol Biol, 234, 779, 10.1006/jmbi.1993.1626 Kriegl, 2014, Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model, Bioorg Med Chem Lett Hess, 2008, GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation, J Chem Theory Comput, 4, 435, 10.1021/ct700301q Tautermann, 2013, Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor, J Med Chem, 56, 8746, 10.1021/jm401219y Berger, 1997, Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature, Biophys J, 72, 2002, 10.1016/S0006-3495(97)78845-3 Best, 2009, Optimized molecular dynamics force fields applied to the helix–coil transition of polypeptides, J Phys Chem B, 113, 9004, 10.1021/jp901540t Lindorff-Larsen, 2010, Improved side-chain torsion potentials for the Amber ff99SB protein force field, Proteins, 78, 1950, 10.1002/prot.22711 Berendsen, 1987, The missing term in effective pair potentials, J Phys Chem, 91, 6269, 10.1021/j100308a038 Joung, 2008, Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations, J Phys Chem B, 112, 9020, 10.1021/jp8001614 Wang, 2004, Development and testing of a general amber force field, J Comput Chem, 25, 1157, 10.1002/jcc.20035 Frisch, 2009 Sousa da Silva, 2012, ACPYPE — AnteChamber PYthon Parser interfacE, BMC Res Notes, 5, 367, 10.1186/1756-0500-5-367 Wolf, 2010, g_membed: efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation, J Comput Chem, 31, 2169, 10.1002/jcc.21507 Berendsen, 1984, Molecular dynamics with coupling to an external bath, J Chem Phys, 81, 3684, 10.1063/1.448118 Bussi, 2007, Canonical sampling through velocity rescaling, J Chem Phys, 126, 014101, 10.1063/1.2408420 Parrinello, 1981, Polymorphic transitions in single crystals: a new molecular dynamics method, J Appl Phys, 52, 7182, 10.1063/1.328693 Essmann, 1995, A smooth particle mesh Ewald method, J Chem Phys, 103, 8577, 10.1063/1.470117 Miyamoto, 1992, Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models, J Comput Chem, 13, 952, 10.1002/jcc.540130805 Hess, 1997, LINCS: a linear constraint solver for molecular simulations, J Comput Chem, 18, 1463, 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H Feenstra, 1999, Improving efficiency of large time-scale molecular dynamics simulations of hydrogen-rich systems, J Comput Chem, 20, 786, 10.1002/(SICI)1096-987X(199906)20:8<786::AID-JCC5>3.0.CO;2-B Viola, 2008, Chemokines and their receptors: drug targets in immunity and inflammation, Annu Rev Pharmacol Toxicol, 48, 171, 10.1146/annurev.pharmtox.48.121806.154841 Bahl, 2010, Chemokine CCR3 antagonists, 153 Trabanino, 2004, First principles predictions of the structure and function of g-protein-coupled receptors: validation for bovine rhodopsin, Biophys J, 86, 1904, 10.1016/S0006-3495(04)74256-3 Wise, 2007, Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation, J Biol Chem, 282, 27935, 10.1074/jbc.M703255200 Surgand, 2006, A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors, Proteins, 62, 509, 10.1002/prot.20768 Martyres, 2008 Global Strategy for the Diagnosis, Management and Prevention of COPD, 2014 Cazzola, 2012, Pharmacology and therapeutics of bronchodilators, Pharmacol Rev, 64, 450, 10.1124/pr.111.004580 Kruse, 2012, Structure and dynamics of the M3 muscarinic acetylcholine receptor, Nature, 482, 552, 10.1038/nature10867 Schmidtke, 2011, Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design, J Am Chem Soc, 133, 18903, 10.1021/ja207494u Katritch, 2014, Allosteric sodium in class A GPCR signaling, Trends Biochem Sci, 39, 233, 10.1016/j.tibs.2014.03.002 Pande, 2010, Everything you wanted to know about Markov State Models but were afraid to ask, Methods, 52, 99, 10.1016/j.ymeth.2010.06.002 Prinz, 2011, Markov models of molecular kinetics: generation and validation, J Chem Phys, 134, 174105, 10.1063/1.3565032